Harvard Medical School
哈佛医学院
Harvard Medical School appears in elsewhere's corpus only as a career waypoint, not as a covered subject in its own right. Feng Shao recounts spending over a year there as a postdoc after finishing his PhD in 2003, in a 5Y Capital–published conversation on drug discovery , and Qiming's Kan Chen describes a path running "from Fudan undergrad all the way to postdoctoral training at Harvard Medical School" in an 暗涌Waves interview . Beyond those biographical mentions, elsewhere's corpus does not profile the institution itself — its history, structure, or standing — so a fuller profile can't be drawn from the material at hand.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
3Sigma Bootcamp Application Countdown | Seeking Frontier Tech Founders Ready to Break the Paradigm
The essence of innovation is stepping outside the boundaries of established paradigms — even when that means a kind of madness others won't understand.
Li Feng in Conversation with Academician Shao Feng: New Trends in Drug Discovery
How Can Basic Research Better Connect with Industry in Biomedicine, a Field Where "the Barrier to Entry Is Low, but the Courtyard Runs Deep"?


